Cibus, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CBUS research report →
Range $10.5 – $12.5
Price Chart
About the company
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients.
- CEO
- Craig Wichner
- IPO
- 2017
- Employees
- 118
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on CBUS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $92.73M
- P/E
- -0.81
- Fwd P/E
- 11.00
- PEG
- -0.01
- P/S
- 20.46
- P/B
- -16.41
- EV/EBITDA
- -2.08
- Div Yield
- 0.00%
- Gross Margin
- 47.95%
- Op Margin
- -1125.55%
- Net Margin
- -2131.38%
- ROE
- -581.53%
- ROIC
- -17.52%
Latest fiscal year · YoY change
- Revenue
- $3.64M-14.6%
- Gross Profit
- $-2,284,000+12.1%
- Op Income
- $-67,464,000
- Net Income
- $-127,085,000+49.4%
- EPS
- $-2.78+74.3%
- OCF Growth
- +12.8%
- FCF Growth
- +13.1%
- 52W High
- $4.19
- 52W Low
- $1.02
- 50D MA
- $1.40
- 200D MA
- $1.80
- Beta
- 1.57
- RSI (14)
- 45
- Avg Volume
- 117.21K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cibus said Q3 progress was led by its sustainable ingredients and rice programs, while it tightened spending and reiterated that it will likely need additional capital in the near term.· November 12, 2026
- Revenue rose to $0.8 million from $0.6 million a year ago, with 9-month revenue up 35% to $3.5 million.
- Q3 net loss improved to $21.9 million from $24.3 million, and EPS narrowed to $0.29 from $0.44.
- Cash was $10.7 million at September 30, 2026; management said that cash should fund operations into early Q1 2027, but additional capital is expected near term.
- Biofragrance moved to a direct sales model with manufacturing underway and partner interest expanding; management now sees up to about $100 million in peak annual revenue for 8 ingredients.
- Rice field testing is now underway in customers’ own varieties in Latin America, with initial commercial launch targeted as early as 2028 and U.S. launch planning still tied to 2029 or 2030.
Cibus reported third-quarter revenue of $0.8 million, up from $0.6 million a year ago. For the first 9 months of 2026, revenue was $3.5 million versus $2.6 million, an increase of 35%, primarily from sustainable ingredients collaborations. R&D expense was $7.9 million versus $10.8 million a year ago, SG&A was $5.4 million versus $5.3 million, and operating expenses fell by about $2.7 million year over year. Net loss was $21.9 million, compared with $24.3 million, and net loss per share was $0.29 versus $0.44. Cash and cash equivalents were $10.7 million at September 30, 2026. Management said existing cash should fund planned operating expenses and capex into early Q1 2027, though it expects to raise additional capital in the near term. The company also said it expects to exit 2026 at about a $35 million annualized net cash usage run rate.
Craig Wichner framed the quarter around Cibus’s three value drivers: near-term platform revenue, future royalties from traits on acres, and deeper partnerships over time. He emphasized Direct Breeding as the core strategic differentiator, arguing it can return edited germplasm in 12 to 15 months in canola, enable multiple edits at once, and avoid inserting editing machinery into plant DNA. His tone was confident and focused on speed, cost, and partnership value, while also stressing that the company is concentrating resources on the two programs closest to revenue: sustainable ingredients and rice.
Carlo Broos highlighted improved cash usage and tighter cost control, saying cash used in operating activities for the first 9 months of 2026 improved by about $7 million, or 19%, versus the same period last year. He cited cash and equivalents of $10.7 million and said the company expects cash to last into early Q1 2027, but will need additional capital soon. On the quarter, he reported revenue of $0.8 million, R&D of $7.9 million, SG&A of $5.4 million, and net loss of $21.9 million, and noted that the $9.8 million royalty liability interest expense was noncash. He also said the company’s cost actions included workforce reductions, lab consolidation, lower consultant spend, simpler legal structures, integrated systems, and more use of technology and AI tools.
Analysts focused mainly on the Direct Breeding platform, the biofragrance commercialization path, and whether other crop opportunities could follow the newly disclosed India mustard work. Management said Direct Breeding is faster and cheaper than conventional breeding because Cibus edits elite varieties directly, without needing to breed out inserted machinery, and can make multiple edits at once. On biofragrances, management said the model is now direct sales through contract manufacturing, with no capex required and gross margins potentially around 50% to 70% as scale improves. On the broader pipeline, Gregory Gocal said Cibus has 9 platforms and is actively looking to partner additional opportunities, while Craig Wichner said future programs should be chosen for fast commercialization and leverage of existing R&D.
The call showed tangible progress in the two programs management says are closest to revenue: biofragrances and rice. Biofragrances now have partner approvals for the first two ingredients, manufacturing underway, and a much larger peak revenue estimate under a direct sales model, while rice traits are already being tested in customers’ own varieties in Latin America. Management also said multiple other programs are advancing on schedule, including light leaf spot, pod shatter, nutrient use efficiency, and mustard in India.
Cibus still has limited revenue, a net loss, and only $10.7 million in cash, with management expecting to need additional capital in the near term. The company’s commercialization timelines remain multi-year, with rice launch expected as early as 2028 in Latin America and 2029 or 2030 in the U.S., while biofragrance revenue still depends on formulation wins and purchase orders. Several programs are still in development or regulatory staging, so execution and funding remain key risks.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 61.4%
- Shares Outstanding
- 76.64M
- Float Shares
- 47.02M
of shares held by institutions
62 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 11.46M | ▲ 14.68K |
| Vanguard Capital Management LLC | 2.25M | ▼ 49.47K |
| Vanguard Group Inc | 1.24M | ▲ 276.99K |
| Vantage Consulting Group Inc | 1.14M | 0 |
| Transce3nd, LLC | 729.71K | ▲ 698.59K |
| Geode Capital Management, LLC | 595.22K | ▲ 66.98K |
| United Capital Financial Advisors, LLC | 576.04K | 0 |
| Blackrock, Inc. | 481.73K | ▼ 11.07K |
| Vanguard Fiduciary Trust Co | 352.76K | ▲ 42.62K |
| Squarepoint Ops LLC | 310.07K | ▼ 2.27K |
| Susquehanna International Group, Llp | 188.62K | ▲ 188.62K |
| Corient Private Wealth LP | 171.01K | ▲ 6.04K |
Held by 39 ETFs
Biggest fund positions in CBUS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Sauer Noel | other | 1,839 |
| Nov 11, 26 | Stokes Jason | other | 3,519 |
| Nov 11, 26 | Broos Carlo | other | 2,537 |
| Jun 8, 26 | Wichner Craig | other | 1,047,620 |
| Jun 8, 26 | Wichner Craig | other | 894,309 |
| Jun 2, 26 | Finn Mark Terrence | other | 77,586 |
| Jun 2, 26 | Moretti August J | other | 77,586 |
| Jun 2, 26 | RIGGS RORY B | other | 77,586 |
| Jun 2, 26 | Prante Gerhard | other | 64,748 |
| Jun 2, 26 | Lehmann Jean-Pierre Jules | other | 64,748 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CBUS coverage
Recent articles, reports, and earnings notes.
No research on CBUS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CBUS report →Cibus, Inc. (CBUS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
What Cibus (CBUS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
Cibus (CBUS) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 12
Cibus Reports Third Quarter Financial Results and Provides Business Update
globenewswire.com · Nov 12
Cibus to Report Third Quarter 2026 Financial Results on November 12, 2026 After the Market Close and Host Conference Call
globenewswire.com · Nov 3
Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop
globenewswire.com · Sep 28
Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 13
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
zacks.com · Aug 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.